Buy Alunbrig 90mg (brigatinib)30 Tablets Alunbrig 90mg (brigatinib)30 TabletsMore Information on Briganix 90mg 30 Tablets | 98.4 Pharmacy Online
Alunbrig 90mg (brigatinib)30 Tablets
Alunbrig 90mg (brigatinib)30 TabletsMore Information on Briganix 90mg 30 Tablets | 98.4 Pharmacy Online
Brand Name : Briganix
Composition : Brigatinib 90mg
Manufactured by : Beacon Pharmaceuticals
Form : Tablet
Packing : Pack of 30 Tablets
Alunbrig 90mg (brigatinib)30 Tablets Alunbrig 90mg (brigatinib)30 Tablets Alunbrig 90mg (brigatinib)30 Tablets Alunbrig 90mg (brigatinib)30 Tablets Alunbrig 90mg (brigatinib)30 Tablets
Alunbrig 90mg (brigatinib)30 TabletsMore Information on Briganix 90mg 30 Tablets | 98.4 Pharmacy Online
98.4 Pharmacy advice for Briganix 90mg 30 Tablets
- Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with brigatinib; monitor for new or worsening respiratory symptoms (eg, dyspnea, cough), particularly during the first week of initiating.
- Dose-related hypertension reported; control BP prior to treatment; monitor BP after 2 weeks and at least monthly thereafter.
- Bradycardia (HR <50 bpm) reported; monitor HR and BP; monitor more frequently if concomitant use of drugs known to cause bradycardia cannot be avoided.
- May cause visual disturbances; advise patients to report any visual symptoms.
- Increased CPK reported; advise patients to report any unexplained muscle pain, tenderness, or weakness; monitor CPK during treatment.
- Serum pancreatic enzyme elevation reported; monitor lipase and amylase during treatment.
- May cause new or worsening hyperglycemia; assess fasting serum glucose before initiating drug and periodically thereafter; initiate or optimize antihyperglycemic medications as needed.
-
More Information on Briganix 90mg 30 Tablets | 98.4 Pharmacy Online
98.4 Pharmacy advice for Briganix 90mg 30 Tablets
- Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with brigatinib; monitor for new or worsening respiratory symptoms (eg, dyspnea, cough), particularly during the first week of initiating.
- Dose-related hypertension reported; control BP prior to treatment; monitor BP after 2 weeks and at least monthly thereafter.
- Bradycardia (HR <50 bpm) reported; monitor HR and BP; monitor more frequently if concomitant use of drugs known to cause bradycardia cannot be avoided.
- May cause visual disturbances; advise patients to report any visual symptoms.
- Increased CPK reported; advise patients to report any unexplained muscle pain, tenderness, or weakness; monitor CPK during treatment.
- Serum pancreatic enzyme elevation reported; monitor lipase and amylase during treatment.
- May cause new or worsening hyperglycemia; assess fasting serum glucose before initiating drug and periodically thereafter; initiate or optimize antihyperglycemic medications as needed.
Reviews
There are no reviews yet.